Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Efficacy and Tolerability of Disease Modifying Therapies in Late Onset Multiple Sclerosis
Multiple Sclerosis
P9 - Poster Session 9 (12:00 PM-1:00 PM)
9-007

To evaluate the efficacy and tolerability of disease-modifying therapies (DMTs) in late-onset multiple sclerosis (LOMS)

LOMS defined as multiple sclerosis (MS) with clinical onset after the age of 50. The differences of clinical characteristics and prognosis between LOMS and typical onset were demonstrated in previous studies. Although several DMTs for MS has been emerged, current data on outcomes of DMTs in LOMS are still limited.
Forty-four LOMS patients in our clinic were included to the cohort. The prevalence of persistence of no evident disease activity (NEDA) and tolerability of each DMT were determined by retrospective chart review. Relapse, Expanded Disability Status Scale (EDSS) worsening, or new T2 or T1 gadolinium-enhancing lesions on MRI resulted in loss of NEDA status.
Twenty-nine (65.9%) were female and the age at onset was 56.1 +/- 5.1 years. Median disease duration prior to DMTs was 18.6 months. Median follow up was 17.0 months. At 12 months, 68.4% of patients with glatiramer acetate remained in NEDA status as in 66.7%, 53.3%, 50.0% and 45.5% of patients with dimethyl fumarate, teriflunomide, ocrelizumab, and interferons, respectively. During follow up, 38.5% and 37% of patients taking glatiramer acetate and interferons were unable to tolerate the side effects especially injection site reaction. Only 16.7%, 12.5% and 5.3% of patients with dimethyl fumarate, ocrelizumab and teriflunomide were switched therapy because of adverse events. Additional clinical and MRI longitudinal data, full analysis, as well as comparisons will be presented at the annual meeting.

The large proportion of LOMS with DMTs remained on NEDA status at 1 year. The low NEDA rates in ocrelizumab may be due to the disease severity. Injectable DMTs had high rate of adverse events leading to discontinuation of therapy. More studies including controlled trials are needed for better understanding in the benefit of DMTs in LOMS.
Authors/Disclosures
Smathorn Thakolwiboon, MD (Mayo Clinic Health System)
PRESENTER 		Dr. Thakolwiboon has nothing to disclose.
Amputch Karukote, MD Dr. Karukote has nothing to disclose.
GyeongMo Sohn, MD (Inje University – Haeundae Paik Hospital) Dr. Sohn has nothing to disclose.
Dongkwan Jin, MD No disclosure on file
Mirla L. Avila, MD, FÂ鶹´«Ã½Ó³»­ (Texas Tech University Health Sciences Center) Dr. Avila has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Genzyme, BMS, Serono. Dr. Avila has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for biogen, genzyme, BMS. The institution of Dr. Avila has received research support from Texas Tech.